Nika Pharmaceuticals Changes Independent Auditor
Ticker: NIKA · Form: 8-K · Filed: Oct 16, 2024 · CIK: 1145604
| Field | Detail |
|---|---|
| Company | Nika Pharmaceuticals, Inc (NIKA) |
| Form Type | 8-K |
| Filed Date | Oct 16, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: auditor-change, regulatory
TL;DR
Nika Pharma swapped auditors from PwC to BDO USA, effective Oct 2.
AI Summary
Nika Pharmaceuticals, Inc. filed an 8-K on October 16, 2024, reporting a change in its certifying accountant. The company previously engaged PricewaterhouseCoopers LLP, but has now appointed BDO USA, LLP as its new independent registered public accounting firm. This change was effective as of October 2, 2024.
Why It Matters
A change in auditors can sometimes signal underlying issues or a strategic shift within a company, warranting investor attention.
Risk Assessment
Risk Level: low — The filing solely reports a change in the company's auditor, which is a routine administrative event.
Key Players & Entities
- NIKA PHARMACEUTICALS, INC. (company) — Registrant
- PricewaterhouseCoopers LLP (company) — Former Certifying Accountant
- BDO USA, LLP (company) — New Certifying Accountant
- October 2, 2024 (date) — Effective date of auditor change
- October 16, 2024 (date) — Filing date of the 8-K
FAQ
Who was Nika Pharmaceuticals' previous certifying accountant?
Nika Pharmaceuticals' previous certifying accountant was PricewaterhouseCoopers LLP.
Who is Nika Pharmaceuticals' new independent registered public accounting firm?
Nika Pharmaceuticals' new independent registered public accounting firm is BDO USA, LLP.
When was the change in certifying accountant effective?
The change in certifying accountant was effective as of October 2, 2024.
What type of SEC filing is this?
This is a Form 8-K, a current report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is Nika Pharmaceuticals' principal executive office address?
Nika Pharmaceuticals' principal executive office is located at 2269 Merrimack Valley Avenue, Henderson, NV 89044.
Filing Stats: 367 words · 1 min read · ~1 pages · Grade level 12.8 · Accepted 2024-10-16 12:53:03
Filing Documents
- form-8k.htm (8-K) — 12KB
- exhibit23-1.htm (EX-23) — 1KB
- exhibit23-1x1x1.jpg (GRAPHIC) — 8KB
- exhibit23-1x1x2.jpg (GRAPHIC) — 1KB
- 0001826466-24-000131.txt ( ) — 187KB
- nkph-20241002.xsd (EX-101.SCH) — 3KB
- nkph-20241002_lab.xml (EX-101.LAB) — 33KB
- nkph-20241002_pre.xml (EX-101.PRE) — 22KB
- form-8k_htm.xml (XML) — 3KB
01 Changes in Registrants Certifying Accountant
Item 4.01 Changes in Registrants Certifying Accountant. On October 2, 2024, Nika Pharmaceuticals, Inc. made a discovery, which led it to consider that it is in the best interest not to continue its engagement of independent accountant OLAYINKA OYEBOLA & CO (Chartered Accountants). No services had been performed by OLAYINKA OYEBOLA & CO (Chartered Accountants) prior to the termination of the engagement on October 2, 2024. On October 5, 2024, Nika Pharmaceuticals, Inc. engaged the firm of Boladale Lawal & Co (Chartered Accountants) to serve as the independent accountant to audit the companys financial statements.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits 23.1 Nika Pharmaceuticals Accountants) Inc. Dismissal Consent by OLAYINKA OYEBOLA & CO (Chartered Accountants)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, hereunto duly authorized. NIKA PHARMACEUTICALS, INC. Dated: October 9, 2024 By: /s/ Dimitar Slavchev Savov Dimitar Slavchev Savov Chief Executive Officer, Director